At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
pazopanibdrug
Likely dose
pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
In Brief
A Phase 2 clinical trial evaluating pazopanib for Liposarcoma and 2 related conditions. Completed, enrolled 42 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartMar 2012
Primary CompletionOct 2014
Study CompletionMar 2016
TodayJul 2026
First PostedJan 10, 2012
Enrollment StartMar 1, 2012
Primary CompletionOct 1, 2014
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 14.5 years ago
Interventions
pazopanibdrug
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.